Clinical trials: Overall Survival, OS
Metastatic Melanoma
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Brief summary The purpose of this study is to compare how effective, encorafenib plus binimetinib is in the real-world and clinical trial settings.
- Trial name
- NCT05954546
- Testing
- Enco+bini
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Pfizer
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05968599
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 2,731 people
- Sponsor
- Pfizer
Prostatic Neoplasms, Castration-Resistant
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone…
- Trial name
- NCT05520138
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 5,506 people
- Sponsor
- Pfizer
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Diffuse Large B-cell Lymphoma
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
This was a retrospective non-interventional cohort study design using the Centers for Medicare and Medicaid Services (CMS) 100% Medicare data (2015Q1-2020Q4).
- Trial name
- NCT06271369
- Where
- United States
- Volunteers
- 613 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients…
- Trial name
- URANIS (NCT02450812)
- Testing
- Radium-223-dichloride (Xofigo, BAY88-8223)
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Bayer
Non Small Cell Lung Cancer NSCLC
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC…
- Trial name
- POSEIDON (NCT03164616)
- Testing
- Durvalumab, Tremelimumab, Abraxane + carboplatin
- Where
- 175 sites in United States, Brazil and 17 more
- Volunteers
- 1,186 people
- Sponsor
- AstraZeneca